{"symbol":"ABBV","fiscalQuarter":"Q4-2025","reportDate":"2026-02-04","reportTime":"BMO","status":"reported","company":{"name":"AbbVie Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABBV/earnings/Q4-2025","postBrief":{"headline":"AbbVie Beats on EPS, Stock Down 3.79%","keyNumbers":[{"metric":"EPS","actual":"$2.71","expected":"N/A","surprise":"+2.03%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing strength in key product lines.","They acknowledged challenges in the market but expressed confidence in long-term strategies."],"summary":"Overall, management conveyed a cautiously optimistic outlook despite current market challenges. They emphasized the importance of their pipeline and ongoing product performance."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"AbbVie's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 3.79%, likely due to the lack of revenue details and no guidance for the future. Investors may be concerned about the company's outlook amid market challenges.","metaDescription":"AbbVie Inc (ABBV) Q4 2025 earnings: EPS beat by 2.03%. Stock down 3.79%. Full breakdown."}}